Medication Guide App

Generic Lovaza Availability

Lovaza is a brand name of omega-3 polyunsaturated fatty acids, approved by the FDA in the following formulation(s):

LOVAZA (omega-3-acid ethyl esters - capsule;oral)

  • Manufacturer: SMITHKLINE BEECHAM
    Approval date: November 10, 2004

Has a generic version of Lovaza been approved?

No. There is currently no therapeutically equivalent version of Lovaza available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lovaza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Fatty acid composition
    Patent 5,656,667
    Issued: August 12, 1997
    Inventor(s): Breivik; Harald & B.o slashed.rretzen; Bernt & Dahl; Knut Helk.ang.s & Krokan; Hans Einar & B.o slashed.naa; Kaare Harald
    Assignee(s): Norsk Hydro as
    Fatty acid composition comprising at least 80% by weight of omega-3-fatty acids, salts or derivatives thereof, wherein (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z)-4,7,10,13,16,19-docosahexaenoic acid comprises at least 75% by weight of the total fatty acids. The compositions can be used for the treatment or prophylaxis of multiple risk factors for cardiovascular diseases.
    Patent expiration dates:
    • April 10, 2017
      Drug substance
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.